Extreme deviations from the normative model reveal cortical heterogeneity and associations with negative symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies.


Journal

Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664

Informations de publication

Date de publication:
02 Dec 2023
Historique:
received: 20 09 2022
accepted: 09 11 2023
revised: 03 11 2023
medline: 4 12 2023
pubmed: 3 12 2023
entrez: 2 12 2023
Statut: epublish

Résumé

There is currently no quantifiable method to predict long-term clinical outcomes in patients presenting with a first episode of psychosis. A major barrier to developing useful markers for this is biological heterogeneity, where many different pathological mechanisms may underly the same set of symptoms in different individuals. Normative modelling has been used to quantify this heterogeneity in established psychotic disorders by identifying regions of the cortex which are thinner than expected based on a normative healthy population range. These brain atypicalities are measured at the individual level and therefore potentially useful in a clinical setting. However, it is still unclear whether alterations in individual brain structure can be detected at the time of the first psychotic episode, and whether they are associated with subsequent clinical outcomes. We applied normative modelling of cortical thickness to a sample of first-episode psychosis patients, with the aim of quantifying heterogeneity and to use any pattern of cortical atypicality to predict symptoms and response to antipsychotic medication at timepoints from baseline up to 95 weeks (median follow-ups = 4). T1-weighted brain magnetic resonance images from the GAP and OPTiMiSE samples were processed with Freesurfer V6.0.0 yielding 148 cortical thickness features. An existing normative model of cortical thickness (n = 37,126) was adapted to integrate data from each clinical site and account for effects of gender and site. Our test sample consisted of control participants (n = 149, mean age = 26, SD = 6.7) and patient data (n = 295, mean age = 26, SD = 6.7), this sample was used for estimating deviations from the normative model and subsequent statistical analysis. For each individual, the 148 cortical thickness features were mapped to centiles of the normative distribution and converted to z-scores reflecting the distance from the population mean. Individual cortical thickness metrics of +/- 2.6 standard deviations from the mean were considered extreme deviations from the norm. We found that no more than 6.4% of psychosis patients had extreme deviations in a single brain region (regional overlap) demonstrating a high degree of heterogeneity. Mann-Whitney U tests were run on z-scores for each region and significantly lower z-scores were observed in FEP patients in the frontal, temporal, parietal and occipital lobes. Finally, linear mixed-effects modelling showed that negative deviations in cortical thickness in parietal and temporal regions at baseline are related to more severe negative symptoms over the medium-term. This study shows that even at the early stage of symptom onset normative modelling provides a framework to identify individualised cortical markers which can be used for early personalised intervention and stratification.

Identifiants

pubmed: 38042835
doi: 10.1038/s41398-023-02661-6
pii: 10.1038/s41398-023-02661-6
pmc: PMC10693627
doi:

Substances chimiques

Antipsychotic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

373

Subventions

Organisme : NIMH NIH HHS
ID : P50 MH115846
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH124639
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

Am J Psychiatry. 2010 Jul;167(7):748-51
pubmed: 20595427
Schizophr Bull. 2021 Mar 16;47(2):444-455
pubmed: 33057670
Schizophr Res. 2016 Jul;174(1-3):165-171
pubmed: 27131912
J Neurosci Methods. 2014 Jun 15;230:37-50
pubmed: 24785589
Psychol Med. 2020 Jul;50(9):1452-1462
pubmed: 31364523
Schizophr Bull. 2006 Apr;32(2):214-9
pubmed: 16481659
JAMA Psychiatry. 2013 Oct;70(10):1031-40
pubmed: 23945954
Neuroimage. 2022 Dec 1;264:119699
pubmed: 36272672
Schizophr Bull. 2015 May;41(3):574-83
pubmed: 25800248
PLoS One. 2014 Jun 30;9(6):e101372
pubmed: 24979583
Lancet Psychiatry. 2018 Oct;5(10):797-807
pubmed: 30115598
JAMA Psychiatry. 2018 Apr 1;75(4):396-404
pubmed: 29450447
Biol Psychiatry. 2016 Oct 1;80(7):552-61
pubmed: 26927419
Schizophr Bull. 2014 Nov;40(6):1509-17
pubmed: 24345517
Lancet Psychiatry. 2018 Nov;5(11):885-894
pubmed: 30322824
Schizophr Res. 2015 Oct;168(1-2):84-91
pubmed: 26265299
Hum Brain Mapp. 2021 Jun 1;42(8):2546-2555
pubmed: 33638594
Psychol Med. 2023 Jun;53(8):3471-3479
pubmed: 35197142
Am J Psychiatry. 2005 Mar;162(3):441-9
pubmed: 15741458
Psychol Med. 2021 Jan;51(2):340-350
pubmed: 31858920
Schizophr Bull. 2021 Jul 8;47(4):1029-1038
pubmed: 33547470
World Psychiatry. 2014 Oct;13(3):275-87
pubmed: 25273301
JAMA Psychiatry. 2018 Nov 1;75(11):1146-1155
pubmed: 30304337
Schizophr Res. 2009 Nov;115(1):82-7
pubmed: 19775869
PLoS One. 2022 Dec 8;17(12):e0278776
pubmed: 36480551
Schizophr Res. 2012 Aug;139(1-3):218-24
pubmed: 22658528

Auteurs

Amanda Worker (A)

Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Pierre Berthert (P)

Department of Psychology, University of Oslo, Oslo, Norway.
Norwegian Center for Mental Disorders Research (NORMENT), University of Oslo, and Oslo University Hospital, Oslo, Norway.

Andrew J Lawrence (AJ)

Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Seyed Mostafa Kia (SM)

Donders Institute for Brain, Cognition, and Behavior, Radboud University, Nijmegen, the Netherlands.
Department of Cognitive Neuroscience, Radboud University Medical Center, Nijmegen, the Netherlands.
Department of Cognitive Science and Artificial Intelligence, Tilburg University, Tilburg, the Netherlands.

Celso Arango (C)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañon, IiSGM, CIBERSAM, School of Medicine, Universidad Complutense Madrid, Madrid, Spain.

Richard Dinga (R)

Donders Institute for Brain, Cognition, and Behavior, Radboud University, Nijmegen, the Netherlands.
Department of Cognitive Neuroscience, Radboud University Medical Center, Nijmegen, the Netherlands.

Silvana Galderisi (S)

University of Campania "Luigi Vanvitelli", Naples, Italy.

Birte Glenthøj (B)

Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS) and Center for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Center, Glostrup, Copenhagen University Hospital - Mental Health Services CPH, Copenhagen, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

René S Kahn (RS)

Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Anoushka Leslie (A)

Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Robin M Murray (RM)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Carmine M Pariante (CM)

National Institute for Health Research Mental Health Biomedical Research Centre, South London and Maudsley National Health Service Foundation Trust and King's College London, London, UK.
Biological Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Christos Pantelis (C)

Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Carlton South, Victoria, Australia.

Mark Weiser (M)

Department of Psychiatry, Sheba Medical Center, Tel Hashomer, Tel Aviv, 52621, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Inge Winter-van Rossum (I)

Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.

Philip McGuire (P)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Paola Dazzan (P)

Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
National Institute for Health Research Mental Health Biomedical Research Centre, South London and Maudsley National Health Service Foundation Trust and King's College London, London, UK.

Andre F Marquand (AF)

Donders Institute for Brain, Cognition, and Behavior, Radboud University, Nijmegen, the Netherlands. andre.marquand@donders.ru.nl.
Department of Cognitive Neuroscience, Radboud University Medical Center, Nijmegen, the Netherlands. andre.marquand@donders.ru.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH